Results 31 to 40 of about 2,156,166 (288)

Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review [PDF]

Pharmacia
Monoclonal antibodies (mAbs) are immunoglobulins with practically absolute specificity (monospecificity) for a particular antigen (epitope). Over the past three decades, monoclonal antibodies have undergone a remarkable transformation, evolving from ...
Petar Yordanov Atanasov, Maria Georgieva Moneva-Sakelarieva, Yozlem Ali Kobakova, Stefka Achkova Ivanova, Maria Vakrilova Becheva, Angelina Georgieva Kirkova-Bogdanova, Maria Sevdelinova Chaneva, Ventseslava Petrova Atanasova, Radoslav Fedeev Todorov, Nikolay Zarkov Bashev, Ismail Elhanov Bashov, Adel Habib Ibrahim   +11 more
doaj   +3 more sources

38227 Specific and highly potent human monoclonal antibodies against SARS-CoV-2

Journal of Clinical and Translational Science, 2021
IMPACT: We devised a new method to produce highly potent SARS-CoV2-specific that can be used to treat severely ill patients with Covid-19. OBJECTIVES/GOALS: Neutralizing antibodies against SARS-CoV-2 are thought to offer the most immediate and effective ...
Mayara Garcia de Mattos Barbosa, Hui Liu, Daniel Huynh, Jeffrey L. Platt, Marilia Cascalho   +4 more
doaj   +1 more source

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

Antibodies, 2019
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole ...
Erik Doevendans, H. Schellekens
semanticscholar   +1 more source

Future perspectives of therapeutic monoclonal antibodies.

Immunotherapy, 2019
Attention to therapeutic monoclonal antibodies has been dramatically increasing year by year. Their highly specific targeting of antigens can provide very effective medical treatment, and the advent of molecular-targeting medicine is allowing development
K. Tsumoto, Yushi Isozaki, H. Yagami, M. Tomita   +3 more
semanticscholar   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra

Онкогематология, 2022
Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contraThe review presents the results of a combined analysis of literature data and own clinical observations regarding the safety and feasibility of using ...
K. A. Sychevskaya, S. K. Kravchenko
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors

Frontiers in Bioengineering and Biotechnology
The Chinese hamster ovarian (CHO) cells serve as a common choice in biopharmaceutical production, traditionally cultivated in stirred tank bioreactors (STRs).
Xuekun Wang, Xuekun Wang, Jin Xu, Jin Xu, Jin Xu, Qingcheng Guo, Qingcheng Guo, Qingcheng Guo, Qingcheng Guo, Zhenhua Li, Zhenhua Li, Zhenhua Li, Jiawei Cao, Jiawei Cao, Jiawei Cao, Rongrong Fu, Rongrong Fu, Mengjiao Xu, Mengjiao Xu, Xiang Zhao, Xiang Zhao, Fugui Wang, Fugui Wang, Xinmeng Zhang, Taimin Dong, Xu Li, Weizhu Qian, Weizhu Qian, Weizhu Qian, Shen Hou, Shen Hou, Shen Hou, Lusha Ji, Lusha Ji, Lusha Ji, Dapeng Zhang, Dapeng Zhang, Dapeng Zhang, Huaizu Guo, Huaizu Guo, Huaizu Guo, Huaizu Guo   +41 more
doaj   +1 more source

Monoclonal Antibodies as Immune Modulators for Cancer Therapy

Canadian Journal of Infectious Diseases, 1992
Monoclonal antibodies may modulate immune and/or biological responses alone, or as carriers of specific agents. Monoclonal antibodies directed against tumours may be indirectly cytotoxic by modulation of antibody-dependent, cell-mediated cytotoxicity or ...
Robert O Dillman
doaj   +1 more source

Substrate specificity of Burkholderia pseudomallei multidrug transporters is influenced by the hydrophilic patch in the substrate‐binding pocket

FEBS Letters, EarlyView.
Multidrug transporters BpeB and BpeF from the Gram‐negative pathogen Burkholderia pseudomallei have a hydrophilic patch in their substrate‐binding pocket. Drug susceptibility tests and growth curve analyses using an Escherichia coli recombinant expression system revealed that the hydrophilic patches of BpeB and BpeF are involved in the substrate ...
Ui Okada, Satoshi Murakami
wiley   +1 more source